Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [PMID: 35978668 DOI: 10.4254/wjh.v14.i6.1053]
Corresponding Author of This Article
Iman Ibrahim Salama, MD, Professor, Department of Community Medicine Research, National Research Center, El Tahrir Street-Doki-Giza_Egypt, Giza 12622, Dokki, Egypt. salamaiman@yahoo.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jun 27, 2022; 14(6): 1053-1073 Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1053
Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
Iman Ibrahim Salama, Hala M Raslan, Ghada A Abdel-Latif, Somaia I Salama, Samia M Sami, Fatma A Shaaban, Aida M Abdelmohsen, Walaa A Fouad
Iman Ibrahim Salama, Ghada A Abdel-Latif, Somaia I Salama, Aida M Abdelmohsen, Walaa A Fouad, Department of Community Medicine Research, National Research Center, Giza 12622, Dokki, Egypt
Hala M Raslan, Department of Internal Medicine, National Research Center, Giza 12622, Dokki, Egypt
Samia M Sami, Fatma A Shaaban, Department of Child Health, National Research Center, Giza 12622, Dokki, Egypt
Author contributions: Salama II and Raslan HA designed the review steps; Salama II, Salama SI, Abdel-Latif GA, Sami SM, and Shaaban FA were responsible for writing the minireview; Abdelmohsen AM and Fouad WA were responsible for manuscript reviewing; Salama II, Raslan HA, Salama SI, and Abdel-Latif GA did the final revision; Sami SM did the final editing; all the authors reviewed and approved the minireview.
Conflict-of-interest statement: All authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Iman Ibrahim Salama, MD, Professor, Department of Community Medicine Research, National Research Center, El Tahrir Street-Doki-Giza_Egypt, Giza 12622, Dokki, Egypt. salamaiman@yahoo.com
Received: January 17, 2022 Peer-review started: January 17, 2022 First decision: March 8, 2022 Revised: April 1, 2022 Accepted: May 22, 2022 Article in press: May 22, 2022 Published online: June 27, 2022
Core Tip
Core Tip: Direct-acting antivirals (DAAs) are achieving an over 85% sustained virological response in treating hepatitis C virus (HCV) infection. The risk factors for DAAs failure include old males, cirrhosis, and the presence of resistance-associated substitutions mainly in genotypes 1a and 3. The higher rate of hepatocellular carcinoma after DAA therapy may be due to offering DAA regimens to patients with advanced liver fibrosis and cirrhosis, where using interferon was contraindicated. The change in the growth of pre-existing subclinical, undetectable hepatocellular carcinoma upon DAA treatment might be a cause. DAAs are effective in treating HCV-associated mixed cryoglobulinemia, thrombocytopenia, rheumatological, renal, and cardiovascular diseases.
